2,009 Shares in Stryker Corporation $SYK Bought by TrustBank

TrustBank bought a new position in shares of Stryker Corporation (NYSE:SYK) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,009 shares of the medical technology company’s stock, valued at approximately $706,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. VanderPol Investments L.L.C. raised its stake in shares of Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after acquiring an additional 28 shares during the period. Lantz Financial LLC raised its stake in shares of Stryker by 5.0% in the third quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock valued at $225,000 after acquiring an additional 29 shares during the period. Stonebridge Capital Advisors LLC raised its stake in shares of Stryker by 0.4% in the third quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock valued at $2,661,000 after acquiring an additional 29 shares during the period. Tcfg Wealth Management LLC raised its stake in shares of Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after acquiring an additional 29 shares during the period. Finally, Sompo Asset Management Co. Ltd. increased its stake in Stryker by 1.3% in the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 2,390 shares of the medical technology company’s stock worth $946,000 after buying an additional 30 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 1.1%

Shares of Stryker stock opened at $313.08 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The firm’s 50-day moving average is $324.33 and its two-hundred day moving average is $349.12. The stock has a market cap of $120.02 billion, a price-to-earnings ratio of 36.24, a PEG ratio of 1.99 and a beta of 0.80.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the company earned $2.84 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Canaccord Genuity Group reduced their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.